立普妥改善中风后肾损害

yuji8

Post-Stroke Patients Treated With Lipitor Demonstrated Significant Improvement Or Stabilization Of Kidney Function

Pfizer announced that post-stroke or mini-stroke patients treated with Lipitor(R) (atorvastatin calcium) Tablets 80 mg had stabilization or improvement in kidney function. These results were demonstrated in patients with or without chronic kidney disease, metabolic syndrome or type 2 diabetes. This post-hoc analysis of the landmark Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study, was presented at the Annual Scientific Sessions of the American Heart Association.

About 700,000 Americans and 1.1 million Europeans suffer from a stroke or mini-stroke annually. Data from the SPARCL study show that stroke patients with type 2 diabetes, metabolic syndrome or chronic kidney disease are at increased risk of additional cardiovascular events, compared to patients without these conditions.

Analysis of Changes in Kidney Function in the SPARCL study

In this new post-hoc analysis (planned after the study closed) of the SPARCL study, kidney function was evaluated by estimated glomerular filtration rate (eGFR, mL/min/1.73m2), a standard test to measure how well the kidneys function.

Post-stroke or mini-stroke patients without chronic kidney disease, with chronic kidney disease and with metabolic syndrome treated with Lipitor 80 mg had significantly improved kidney function compared to placebo.

In post-stroke or mini-stroke patients with type 2 diabetes, those treated with Lipitor demonstrated stabilized kidney function, while patients receiving placebo had significantly declined kidney function during the trial.

\"These results are especially significant for post-stroke diabetic patients because they are more likely to develop progressive kidney disease,\" said Dr. Vito Campese, chief of the division of nephrology/hypertension at the University of Southern California. \"With Lipitor we were able to stabilize patients' kidney function, and given the established relationship between progressive kidney disease and cardiovascular outcome, this may contribute to reducing cardiovascular events. These results are similar to findings from the Treating to New Targets study which found that patients with coronary heart disease treated with Lipitor had stabilized and even improved kidney function.\"

http://www.medicalnewstoday.com/articles/87902.php